Free Trial
LON:STX

Shield Therapeutics (STX) Share Price, News & Analysis

Shield Therapeutics logo
GBX 4.60 +0.01 (+0.22%)
As of 08:18 AM Eastern

About Shield Therapeutics Stock (LON:STX)

Key Stats

Today's Range
4.60
5.10
50-Day Range
2.28
4.59
52-Week Range
1.90
5.87
Volume
12.88 million shs
Average Volume
2.16 million shs
Market Capitalization
£45.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive STX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STX Stock News Headlines

Buffett to put 90% of his money in this one stock?
CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%.
Shield Therapeutics awards CEO share options
Shield Thera Regulatory News
See More Headlines

STX Stock Analysis - Frequently Asked Questions

Shield Therapeutics' stock was trading at GBX 2.70 on January 1st, 2025. Since then, STX stock has increased by 78.7% and is now trading at GBX 4.83.

Shield Therapeutics plc (LON:STX) released its quarterly earnings data on Thursday, April, 24th. The company reported ($3.00) EPS for the quarter. Shield Therapeutics had a negative trailing twelve-month return on equity of 470.50% and a negative net margin of 173.43%.

Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), AstraZeneca (AZN), Model N (MODN), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS) and Cellectis (CLLS).

Company Calendar

Last Earnings
4/24/2025
Today
7/24/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Computer Hardware
Current Symbol
LON:STX
CIK
N/A
Fax
N/A
Employees
40,000
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (3.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
68.19
P/E Growth
N/A
Net Income
-£36.28 million
Net Margins
-173.43%
Pretax Margin
N/A
Return on Equity
-470.50%
Return on Assets
-47.85%

Debt

Debt-to-Equity Ratio
3,691.50
Current Ratio
1.05
Quick Ratio
2.16

Sales & Book Value

Annual Sales
£20.92 million
Price / Sales
2.28
Cash Flow
GBX 0.76 per share
Price / Cash Flow
6.36
Book Value
GBX 0.05 per share
Price / Book
88.17

Miscellaneous

Outstanding Shares
986,864,211
Free Float
N/A
Market Cap
£47.62 million
Optionable
Not Optionable
Beta
1.42
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (LON:STX) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners